Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | HTR5A | P47898 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949690 | 0.83 | HDAC1 (0.56) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL2770342 | 0.79 | PKM (0.47) | KMT2AALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL27875045 | 0.77 | KMT2A (0.48) | KMT2AALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL7324763 | 0.75 | SSTR4 (0.52) | KMT2AMEN1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL14004878 | 0.73 | HDAC3 (0.66) | KMT2AMEN1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL4260280 | 0.73 | HDAC1 (0.47) | KMT2AMEN1ALDH1A1HDAC3HDAC1 | |
| SCHEMBL17607355 | 0.72 | TBXAS1 (0.43) | HDAC3HDAC1HDAC2TBXAS1HDAC4 | |
| SCHEMBL5890773 | 0.72 | RIPK1 (0.63) | ALDH1A1RIPK1NAMPTTRPM8HTR2C | |
| SCHEMBL7332333 | 0.71 | RIPK1 (0.51) | KMT2AALDH1A1RIPK1NAMPTTRPM8 | |
| SCHEMBL5784249 | 0.70 | KDM4E (0.46) | KMT2AALDH1A1RIPK1NAMPTGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2006-01-26 | — | — | US | disclosed |
| EP-1551795-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035525-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC6 | KMT2A 76/4885MEN1 2765/4885ALDH1A1 828/4885 |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | HDAC1, AADAC, HDAC11 | KMT2A 140/4885MEN1 3679/4885ALDH1A1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.